Predicting toxicity in the drug development pipeline

July 19, 2012

University College Dublin researchers have reported in Molecular & Cellular Proteomics on a proof-of-principle study that may benefit the pharmaceutical industry in the future by providing a roadmap for large scale pre-clinical toxicology biomarker verification studies.

It is not currently possible to predict accurately and at an early stage whether there are toxicity issues with candidate drugs. This shortcoming of existing toxicology evaluation methods can not only create a bottleneck in the pipeline but can sometimes lead to the withdrawal of drugs from the market.

The study involved the molecular profiling of models that had been exposed to known toxic insults in an effort to derive the associated biomarker signatures. Forty-eight candidate biomarkers of liver toxicity were assembled from a discovery proteomics screen of liver in a hepatotoxicant treated rat model using label free liquid chromatography mass spectrometry (LC-MS); a previous transcriptomics study of the sample samples and from literature sources.

The team developed and optimised a selected reaction monitoring assay (SRM) in order to quantify the proteins in this putative biomarker panel. This revealed a panel highly enriched for proteins that had been changed significantly as a result of toxicant exposure .   

Dr. Ben Collins, first author and Agilent UCD Newman Fellow, explains, “The idea was to use transcriptomics,  and proteomics and to combine the data to provide earlier markers . Although this study focused on one hepatotoxic compound, there is sufficient flexibility in the approach used to allow medium to high throughput for large scale verification studies involving large numbers of well- defined toxicants and ultimately for more sensitive toxicology evaluation for drugs under early development”.

Team leader and corresponding author, Professor Steve Pennington adds, “We are now working to extend this approach to more readily accessible sample types, such as blood, and are applyijng it in other studies for diagnostics for chronic conditions, such as cancer, cardiovascular disease, and arthritis. With supporti from Agilent are now establishing a dedicated lab to undertake these SRM-based validation studies”.

Explore further: GEN reports on nanotechology's impact on mass spectrometry

More information: Collins, BC et al; Development of a pharmaceutical hepatotoxicity biomarker panel using a discovery to targeted proteomics approach. Molecular & Cellular Proteomics (2012) doi: 10.1074/mcp.M111.016493

Related Stories

GEN reports on nanotechology's impact on mass spectrometry

August 4, 2011
A move toward smaller and smaller sample sizes is leading to a new generation of mass spectrometry instrumentation, reports Genetic Engineering & Biotechnology News (GEN). From a specific application point of view, novel ...

Cancer biomarkers re-evaluated

July 19, 2012
(Medical Xpress) -- Researchers from ETH Zurich have developed a procedure to test the clinical benefits of cancer biomarkers. The method could radically shorten the path from the lab to their application.

Polyphenol-rich diet could reduce cardiovascular risk

December 15, 2011
(Medical Xpress) -- A diet high in polyphenols could help reduce the risk of cardiovascular disease and associated health risks, according to a new study by the University of Glasgow.

New prostate cancer biomarkers move closer to clinical use

June 17, 2011
Conway Fellow, Professor William Watson and Professor John Fitzpatrick, UCD School of Medicine and Medical Science and Mater Misericordiae University Hospital recently received a translational research award for the validation ...

Recommended for you

Using barcodes to trace cell development

August 16, 2017
How do the multiple different cell types in the blood develop? Scientists have been pursuing this question for a long time. According to the classical model, different developmental lines branch out like in a tree. The tree ...

After a half-century of attempts, psilocybin has finally been synthesized in the lab

August 16, 2017
A team of researchers at Friedrich Schiller University Jena has figured how out to make psilocybin, the chemical responsible for creating hallucinations in people who consume the mushrooms that produce it naturally. In their ...

The unexpected role of a well-known gene in creating blood

August 16, 2017
One of the first organ systems to form and function in the embryo is the cardiovascular system: in fact, this developmental process starts so early that scientists still have many unresolved questions on the origin of the ...

Researchers unlock clues to how cells move through the body

August 16, 2017
During its 120-day cycle the circulatory system transports red blood cells and nutrients throughout the human body. This system helps keep the body in balance and fight against infections and diseases by filtering old or ...

Eating habits affect skin's protection against sun

August 15, 2017
Sunbathers may want to avoid midnight snacks before catching some rays.

Therapeutic fusion protein could mitigate blood vessel damage from cardiovascular disease

August 15, 2017
Scientists from Boston Children's Hospital Vascular Biology Program have revealed an engineered fusion protein that could recover blood vessel health following the onset of hypertension, atherosclerosis, stroke, heart attack, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.